Overview

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

Status:
Completed
Trial end date:
2004-05-25
Target enrollment:
Participant gender:
Summary
A 48-week study to investigate the safety and effectiveness of a new compact formulation of two already FDA-approved anti-HIV drugs in subjects who have already been receiving treatment for their HIV infection.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
ViiV Healthcare
Treatments:
Abacavir
Dideoxynucleosides
Lamivudine
Tenofovir